ESR1 and breast cancer: Furthermore, we observed the pharmacological inhibition of YAP1 phenocopies RASSF1A-mediated suppression of ERα and FOXM1 expression, suggesting that drugs that target YAP1 might compensate for the loss of RASSF1A function in ER+ breast cancer cells.